Free cash flow
Regeneron Pharmaceuticals Free cash flow decreased by 8.0% to $848.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.0%, from $815.80M to $848.30M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -11.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Detailed definition
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Peer comparison
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
cf_free_cash_flowHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $478.20M | $3.28B | $2.22B | $1.96B | $410.80M | $486.40M | $1.57B | $1.19B | $909.40M | $938.30M | $838.30M | $1.38B | $173.50M | $1.05B | $1.06B | $815.80M | $925.40M | $1.42B | $922.00M | $848.30M |
| QoQ Change | — | +586.0% | -32.4% | -11.6% | -79.0% | +18.4% | +222.3% | -24.1% | -23.5% | +3.2% | -10.7% | +64.5% | -87.4% | +504.8% | +1.3% | -23.3% | +13.4% | +53.2% | -34.9% | -8.0% |
| YoY Change | — | — | — | — | -14.1% | -85.2% | -29.3% | -39.3% | +121.4% | +92.9% | -46.5% | +15.9% | -80.9% | +11.8% | +26.8% | -40.8% | +433.4% | +35.1% | -13.3% | +4.0% |
Free cash flow at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's free cash flow?
- Regeneron Pharmaceuticals (REGN) reported free cash flow of $848.30M in Q1 2026.
- How has Regeneron Pharmaceuticals's free cash flow changed year-over-year?
- Regeneron Pharmaceuticals's free cash flow increased by 4.0% year-over-year, from $815.80M to $848.30M.
- What is the long-term trend for Regeneron Pharmaceuticals's free cash flow?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's free cash flow has grown at a -11.1% compound annual growth rate (CAGR), from $6.53B to $4.08B.
- What does free cash flow mean?
- The cash a company has left over after paying for its operating expenses and capital investments.